CClinicalTrials.gg
CompletedNCT00107744ProBPUpdated Apr 12, 2023Results posted

Clinical Trial of Protein and Blood Pressure

An interventional study of Soy protein-milk protein-carbohydrate and Milk protein-carbohydrate-soy protein in Hypertension and Hypercholesterolemia, sponsored by Tulane University. Completed. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Tulane University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Study summary

The purpose of this randomized, double-blind, controlled trial is to examine the effect of soybean protein supplementation on blood pressure in persons with prehypertension or stage-1 hypertension.

Read the detailed description

Background: Epidemiologic studies suggest that vegetable protein intake is inversely related to blood pressure.

Objectives: To examine the effect of soybean protein supplementation on blood pressure in persons with prehypertension or stage-1 hypertension

Design: Randomized, double-blind, controlled trial

Study Participants: 350 participants, aged 35-64 years, with an initial untreated systolic blood pressure of 130-159 mmHg and/or diastolic blood pressure of 80-99 mmHg

Intervention: Study participants will be randomly assigned to take 40-grams of isolated soybean protein supplements per day or complex carbohydrate control for 12 weeks.

Outcomes: Blood pressure measurements will be obtained using random-zero sphygmomanometers at baseline and during the trial at weeks 6 and 12. Net changes in systolic and diastolic blood pressure before and after the intervention is the primary outcome.

02

Conditions studied

  • Hypertension
  • Hypercholesterolemia

Keywords

  • Blood Pressure; Lipids; Dietary Protein
03

In context

Hypercholesterolemia

1,238 studies on the registry are indexed under Hypercholesterolemia; 110 are open to participants now.

This study's enrollment of 352 is above the median of 100 across 992 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Tulane University is the lead sponsor of 98 studies on the registry; 30 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Systolic BP of 120 to 159 mm Hg and diastolic BP of 80 to 95 mm Hg (average of 6 measurements at 2 screening visits)
  2. Willing to participate in all aspects of the study

Exclusion criteria

Exclusion Criteria:

  1. Consumption of dietary protein greater than or equal to 1.63 grams/kg per day, as determined by two 24-hour dietary recalls
  2. Stage-2 or higher severe hypertension (systolic BP greater than or equal to 160 mm Hg and/or diastolic BP greater than or equal to 95 mm Hg)
  3. Use of antihypertensive medications or medications that affect BP
  4. History of clinical heart disease (e.g., angina/heart attack, coronary revascularization, heart failure, stroke/transient ischemic attack, peripheral arterial disease)
  5. Kidney disease (serum creatinine level greater than or equal to 1.7 mg/dL for men and greater than or equal to 1.5 mg/dL for women)
  6. Current hypercholesterolemia (fasting serum total cholesterol greater than or equal to 240 mg/dL) or use of cholesterol-lowering medications
  7. Current diabetes (fasting serum glucose greater than or equal to 126 mg/dL) or use of insulin or oral hypoglycemic agents
  8. Severe obesity (body mass index greater than or equal to 40 kg/m²)
  9. Current use of prescription weight loss medications, underwent weight loss surgery, and/or experienced weight loss greater than 15 pounds within the 6 months prior to study entry
  10. Cancer (except non-melanoma skin cancer) that required treatment during the year prior to study entry
  11. Consumption of more than 14 alcoholic beverages per week
  12. Current participation in another medical study
  13. Consumption of milk or soy protein greater than or equal to the 90th percentile of intake in the U.S. general population
  14. Has another member of the household participating in the study
  15. Study employees or living with study employees
  16. Allergy or intolerance to soy protein or milk protein products
  17. Allergy to aspartame
  18. Plans to move out of the study area (greater than or equal to 50 miles from the study site) and has difficulty coming to the study site
  19. Inability or unwillingness to cooperate during the screening visits
  20. Poor compliance during the screening period (intake of less than 85% of supplements)
  21. Pregnant or plans to become pregnant during the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
352 participants (actual)

Study arms

  • Active comparator
    Soy protein-milk protein-carbohydrate

    Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.

    Dietary Supplement: Soy protein-milk protein-carbohydrate

  • Active comparator
    Milk protein-carbohydrate-soy protein

    Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.

    Dietary Supplement: Milk protein-carbohydrate-soy protein

  • Active comparator
    Carbohydrate-soy protein-milk protein

    Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.

    Dietary Supplement: Carbohydrate-soy protein-milk protein

Interventions

  • Dietary supplementSoy protein-milk protein-carbohydrate

    40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks

  • Dietary supplementMilk protein-carbohydrate-soy protein

    40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.

  • Dietary supplementCarbohydrate-soy protein-milk protein

    40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Systolic Blood Pressure at 8 Weeks

    The change of systolic blood pressure was calculated as the mean of 6 blood pressure values from two 8-week visits minus the mean of 6 values from 2 baseline visits within each intervention phase. At each visit, 3 BP values were measured with a Hawksley random-zero sphygmomanometer by trained and certified observers who were masked to group assignment. BP readings were taken from the right arm with appropriately sized cuffs after the participant had been seated quietly for 5 minutes. The participant was instructed not to eat, smoke, drink alcohol, or exercise for at least 30 minutes before their BP measurements.

    Time frame: Baseline and 8 Weeks

Secondary outcomes

  1. Change From Baseline in Serum LDL-cholesterol at 8 Weeks

    Change in serum LDL-cholesterol was calculated as LDL-cholesterol at 8 weeks minus LDL-cholesterol at baseline. Over-night fasting serum LDL-cholesterol was measured with an enzymatic method.

    Time frame: Baseline and 8 Weeks

  2. Body Weight at 8 Weeks

    Body weight was measured by trained staff using a standard protocol at week 8.

    Time frame: Baseline and 8 Weeks

07

Results

Posted Jul 5, 2018

Participant flow

Intervention 1 (8 Weeks)
Participant flow — Intervention 1 (8 Weeks)
MilestoneSoy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk Protein
Started117117118
Completed101104101
Not completed161317
Intervention 2 (8 Weeks)
Participant flow — Intervention 2 (8 Weeks)
MilestoneSoy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk Protein
Started101104101
Completed939288
Not completed81213
Intervention 3 (8 Weeks)
Participant flow — Intervention 3 (8 Weeks)
MilestoneSoy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk Protein
Started939288
Completed939288
Not completed000

Outcome measures

PrimaryChange From Baseline in Average Systolic Blood Pressure at 8 Weeks

The change of systolic blood pressure was calculated as the mean of 6 blood pressure values from two 8-week visits minus the mean of 6 values from 2 baseline visits within each intervention phase. At each visit, 3 BP values were measured with a Hawksley random-zero sphygmomanometer by trained and certified observers who were masked to group assignment. BP readings were taken from the right arm with appropriately sized cuffs after the participant had been seated quietly for 5 minutes. The participant was instructed not to eat, smoke, drink alcohol, or exercise for at least 30 minutes before their BP measurements.

Time frame:
Baseline and 8 Weeks
Reported as:
Mean · mmHg
Change From Baseline in Average Systolic Blood Pressure at 8 Weeks
mmHgSoy Protein SupplementationMilk Protein SupplementationCarbohydrate Supplementation
Change From Baseline in Average Systolic Blood Pressure at 8 Weeks-1.5 (-2.4 to -0.6)-1.8 (-2.7 to -1.0)0.5 (-0.4 to 1.3)
SecondaryChange From Baseline in Serum LDL-cholesterol at 8 Weeks

Change in serum LDL-cholesterol was calculated as LDL-cholesterol at 8 weeks minus LDL-cholesterol at baseline. Over-night fasting serum LDL-cholesterol was measured with an enzymatic method.

Time frame:
Baseline and 8 Weeks
Reported as:
Mean · mg/dL
Change From Baseline in Serum LDL-cholesterol at 8 Weeks
mg/dLSoy Protein SupplementationMilk Protein SupplementationCarbohydrate Supplementation
Change From Baseline in Serum LDL-cholesterol at 8 Weeks-3.97 (-7.63 to -0.31)-2.56 (-5.40 to 0.28)-1.41 (-4.24 to 1.42)
SecondaryBody Weight at 8 Weeks

Body weight was measured by trained staff using a standard protocol at week 8.

Time frame:
Baseline and 8 Weeks
Reported as:
Mean · kg
Body Weight at 8 Weeks
kgSoy Protein SupplementationMilk Protein SupplementationCarbohydrate Supplementation
Body Weight at 8 Weeks86.2 (84.4 to 88.0)86.6 (84.9 to 88.4)86.7 (84.9 to 88.5)

Adverse events

Collected over Through study completion, an average of 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Soy Protein Supplementation0/352 (0%)0/352 (0%)0/352 (0%)
Milk Protein Supplementation0/352 (0%)0/352 (0%)0/352 (0%)
Carbohydrate Supplementation0/352 (0%)0/352 (0%)0/352 (0%)

Baseline characteristics

Participants randomized to this three-phase cross-over trial.

Age, Continuous
Age, Continuous(years)Soy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk ProteinTotal
Mean48.4 ± 11.546.7 ± 10.748.1 ± 8.747.7 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Soy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk ProteinTotal
Female484950147
Male696868205
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Soy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk ProteinTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American393844121
White787974231
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Soy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk ProteinTotal
United States117117118352
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)Soy Protein-milk Protein-carbohydrateMilk Protein-carbohydrate-soy ProteinCarbohydrate-soy Protein-milk ProteinTotal
Mean127.2 ± 9.3126.7 ± 11.0126.1 ± 9.7126.7 ± 10.0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. doi: 10.1016/S0140-6736(05)17741-1. PubMed 15652604 ↗
  • He J, Wofford MR, Reynolds K, Chen J, Chen CS, Myers L, Minor DL, Elmer PJ, Jones DW, Whelton PK. Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial. Circulation. 2011 Aug 2;124(5):589-95. doi: 10.1161/CIRCULATIONAHA.110.009159. Epub 2011 Jul 18. PubMed 21768541 ↗
  • Wofford MR, Rebholz CM, Reynolds K, Chen J, Chen CS, Myers L, Xu J, Jones DW, Whelton PK, He J. Effect of soy and milk protein supplementation on serum lipid levels: a randomized controlled trial. Eur J Clin Nutr. 2012 Apr;66(4):419-25. doi: 10.1038/ejcn.2011.168. Epub 2011 Sep 28. PubMed 21952693 ↗
  • Rebholz CM, Reynolds K, Wofford MR, Chen J, Kelly TN, Mei H, Whelton PK, He J. Effect of soybean protein on novel cardiovascular disease risk factors: a randomized controlled trial. Eur J Clin Nutr. 2013 Jan;67(1):58-63. doi: 10.1038/ejcn.2012.186. Epub 2012 Nov 28. PubMed 23187956 ↗

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00107744
Lead sponsor
Tulane University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Apr 8, 2005
Start date
Sep 2003
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jul 5, 2018
Last update
Apr 12, 2023

Study contacts

Jiang He, MD, PhD
study chair · Tulane University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion